GlycoVaxyn AG
Development of novel biotechnological methods for the production of glycoconjugates
GlycoVaxyn is a Zurich based biotechnology company dedicated to the development of novel biotechnological methods for the production of glycoconjugates. The approach relies on a proprietary genetic system for the development and production of glycosylated therapeutic proteins used as medications or vaccines in simple bacterial cells (E. coli). GlycoVaxyn offers a solution to produce therapeutic glycoproteins faster and at lower costs. The company will develop its portfolio of novel conjugated vaccines and enter cooperations with life science companies.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
11.02.2015
GSK acquires GlycoVaxyn for CHF200 million (startupticker.ch)
27.01.2015
Glycovaxyn received first milestone payment from Janssen (startupticker.ch)
02.07.2014
Vaccine from GlycoVaxyn enters clinical phase (startupticker.ch)
29.07.2013
GlycoVaxyn AG secures CHF 5.1 million Award from the Wellcome Trust (startupticker.ch)
09.01.2013
GlycoVaxyn Enters Collaboration with Janssen (startupticker.ch)
No milestones
No Jobs
No videos and documents
CTI Start-up Label
CTI Start-up enables entrepreneurs to realize their innovative idea professionally.
In a process of three phases, over forty experienced coaches guide start-up companies on their way to enter the market successfully and attract financing. At the end of the coaching process, the most promising start-up companies have the opportunity to receive the prestigious CTI Start-up ’Label’. In addition, the companies benefit from the wide CTI Start-up network of industry experts, experienced entrepreneurs, business angels, venture capitalists and has access to foundations such as de Vigier, STI, FIT, Gebert, Rüf, etc.
Until today, CTI Start-up reviewed more than 1 800 projects, and awarded over 200 start-up enterprises with the CTI Start-up Label. Over 85% of these companies are still in business and some have shown remarkable growth, which is a sign that CTI Start-up guides them to sustainable success.
CTI also promotes the culture of entrepreneurship at universities, teaching hospitals, technical institutes as well as universities of applied sciences. CTI Entrepreneurship offers workshops to students on how to bring innovation to the market.
ETH Spin-off
http://www.vpf.ethz.ch/transfer/firmgruend/spinoff_list/by_years/2009
Volkswirtschaft-Stiftung
Die eidgenössische Stiftung zur Förderung schweizerischer Volkswirtschaft durch wissenschaftliche Forschung bezweckt die Förderung des Technologietransfers. Jungunternehmen können sich für ein zinsloses Darlehen bewerben.
GlycoVaxyn AG
Development of novel biotechnological methods for the production of glycoconjugates
Website:
www.glycovaxyn.com
GSK
Headquarter:
Schlieren
Foundation Date:
November 2004
Technology:
- Biotech
Sectors:
- Vaccines